Impact of GLP1-RAs on inflammation and endothelial biomarkerS in Type 2 diABetes meLlitus patiEnts: STABLE-GLP1 trial.
This research, called STABLE-GLP1, is studying how a common Type 2 diabetes medicine, semaglutide, influences the body's inflammation and the health of blood vessels. Doctors are comparing people who take semaglutide alongside their usual diabetes care against those who only receive standard care. They are particularly interested in adults with Type 2 diabetes who don't have certain heart or organ problems but have a higher risk of future heart issues. The aim is to understand if semaglutide can help reduce signs of inflammation and improve blood vessel health, which could lead to better long-term health outcomes for people living with Type 2 diabetes.
At a glance
What is this study about?
This study, called STABLE-GLP1, is looking into how a medicine called semaglutide affects people with Type 2 diabetes. Semaglutide is already used to treat Type 2 diabetes, but this research wants to understand more about its extra effects. Specifically, it's focusing on how semaglutide might influence inflammation in the body and the health of your blood vessels. Inflammation is your body's response to injury or illness, but long-term inflammation can be harmful, especially for people with diabetes. Healthy blood vessels are also crucial for overall health.
The researchers are comparing two groups of people with Type 2 diabetes. One group will take semaglutide in addition to their usual diabetes treatment, and the other group will continue with only their usual treatment. The main goal is to measure changes in certain markers in the blood that show inflammation and blood vessel health. They will do this at the beginning of the study and again later to see if there are any differences between the two groups. This will help doctors understand if semaglutide offers benefits beyond just controlling blood sugar.
The study also includes looking at detailed heart scans that some participants may have had previously as part of their routine care. This will help researchers understand if there are links between the changes they see in inflammation and blood vessel markers, and the health of the heart's arteries. They will also keep a close eye on any side effects or issues experienced by participants in both groups to make sure the treatment is safe.
Key takeaways
- This study explores how semaglutide affects inflammation and blood vessel health in Type 2 diabetes.
- It compares semaglutide plus standard care to standard care alone.
- Participants must have Type 2 diabetes and a certain risk of future heart problems.
- The study aims to find additional benefits of semaglutide beyond blood sugar control.
- It lasts about one year and involves blood tests and health monitoring.
- Your participation helps doctors understand more about living with Type 2 diabetes.
Who may be eligible?
To join this study, participants must be at least 18 years old. Both men and women can take part.
You need to have Type 2 diabetes. Importantly, you should not have already been diagnosed with serious heart or blood vessel disease (like a previous heart attack or stroke), or severe damage to your body's organs related to diabetes.
Another key factor is your risk of future heart problems. Doctors will use a scoring tool (called SCORE2-Diabetes) to check if your risk is 10% or higher. This helps them identify people who might benefit most from understanding the effects of semaglutide on inflammation and blood vessel health.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have Type 2 diabetes?
- Have you *not* had a heart attack, stroke, or severe organ damage from diabetes?
- Are you willing to potentially take semaglutide in addition to your current diabetes medicine?
- Are you able to attend appointments for blood tests and health checks for about a year?
What does participation involve?
If you decide to take part, you would continue with your standard diabetes care. Depending on which group you are in, you might also be prescribed semaglutide. You would have regular appointments where doctors will check your general health, take blood samples to measure inflammation and blood vessel markers, and monitor any side effects. These assessments will happen at the start and then again about a year later. The total duration of your active involvement in the study would be approximately 52 weeks (about one year).
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is semaglutide?
Semaglutide is a medicine commonly used to treat Type 2 diabetes, helping to control blood sugar levels.
What does 'inflammation' mean?
Inflammation is your body's natural response to protect itself, but too much or long-term inflammation can be harmful, especially for people with diabetes.
Why is 'blood vessel health' important?
Healthy blood vessels are crucial for carrying blood and oxygen around your body. Diabetes can sometimes affect their health, increasing risks like heart problems.
What about my current diabetes medication?
You will continue with your usual diabetes treatment. If you are in the semaglutide group, you will take this medicine in addition to your current care.
How long will the study last if I join?
Your active participation in the study, including follow-up appointments, will last for about one year.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.